ArticleJournal of pediatric gastroenterology and nutrition2025
Cost-utility analysis of sequential therapies for pediatric-onset eosinophilic esophagitis.
Article in Journal of pediatric gastroenterology and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cost-utility analysis of sequential therapies for pediatric-onset eosinophilic esophagitis.Journal of pediatric gastroenterology and nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesTopical corticosteroids, proton-pump inhibitors (PPI) and elimination diets (ED) are equally recommended as first-line therapies for pediatric eosinophilic esophagitis (EoE). Dupilumab (DUP) is usually used for refractoriness. We aim to assess the cost-utility of all potential sequential treatments for EoE.
methodsA Markov model under the payer's perspective was used to describe induction, maintenance, and reinductions for nonresponders over 10 years. Dietary options included step-up restriction starting from two foods, and from cow's milk (CM). Topical corticosteroids viscous solutions, or budesonide orodispersible tablets (BOT) were considered. Nonresponsiveness led to esophageal dilation. Simulation parameters were defined by systematic review. We deterministically selected the most cost-effective permutation as reference. Incremental cost-utility ratios (ICUR) of each alternative sequence were compared to a willingness-to-pay (WTP) threshold of €30,000. Sequences with the highest number of quality-adjusted life-years (QALY) and the highest QALY below WTP were probabilistically explored. Sensitivity analysis was performed.
resultsPPI-ED(CM)-BOT-DUP was the most cost-effective sequence, resulting in €2373/QALY and 7.20 QALY at the time horizon. DUP-BOT-PPI-ED(CM) gave the uppermost QALY, 7.42, but any iteration was cost-effective, yielding a median ICUR of €323,774/QALY. PPI-BOT-ED(CM)-DUP, however, had a higher chance of being under the WTP (83%), showed a median ICUR of €25,156/QALY and provided 7.31 QALY. An 83% reduction of DUP price was needed to make DUP-BOT-PPI-ED(CM) and PPI-BOT-ED(CM)-DUP equally as efficient.
conclusionsBOT and CM-starting step-up ED are present in both effective and cost-effective sequential treatments for EoE. The option PPI-BOT-ED(CM)-DUP succeeded in approaching the most effective alternative while balancing costs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.